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Introduction: In non–small-cell lung cancer, an exon 19 deletion 
and an L858R point mutation in the epidermal growth factor recep-
tor (EGFR) are predictors of a response to EGFR-tyrosine kinase 
inhibitors. However, it is uncertain whether other uncommon EGFR 
mutations are associated with sensitivity to EGFR-tyrosine kinase 
inhibitors.
Methods: A post-hoc analysis to assess prognostic factors was 
performed with the use of patients with EGFR mutations (exon 
19 deletion, L858R, G719X, and L861Q) who were treated with 
gefitinib in the NEJ002 study, which compared gefitinib with 
 carboplatin-paclitaxel as the first-line therapy.
Results: In the NEJ002 study, 225 patients with EGFR mutations 
received gefitinib at any treatment line. The Cox proportional hazards 
model indicated that performance status, response to chemotherapy, 
response to gefitinib, and mutation types were significant prognos-
tic factors. Overall survival (OS) was significantly shorter among 
patients with uncommon EGFR mutations (G719X or L861Q) com-
pared with OS of those with common EGFR mutations (12 versus 
28.4 months; p = 0.002). In the gefitinib group (n = 114), patients 
with uncommon EGFR mutations had a significantly shorter OS 
(11.9 versus 29.3 months; p < 0.001). By contrast, OS was similar 
between patients with uncommon mutations and those with common 
mutations in the carboplatin-paclitaxel group (n = 111; 22.8 versus 
28 months; p = 0.358).
Conclusions: The post-hoc analyses clearly demonstrated shorter 
survival for gefitinib-treated patients with uncommon EGFR muta-
tions compared with the survival of those with common mutations 
and suggest that the first-line chemotherapy may be relatively effec-
tive for non–small-cell lung cancer with uncommon EGFR mutations.
Key Words: Gefitinib, G719X, L861Q, NEJ002, Uncommon epider-
mal growth factor receptor mutations.
(J Thorac Oncol. 2014;9: 189–194)
The clinical efficacy of epidermal growth factor  receptor-tyrosine kinase inhibitors (EGFR-TKIs), such 
as gefitinib and erlotinib, has been demonstrated in non–
small-cell lung cancer (NSCLC) patients in whom standard 
chemotherapy has failed.1,2 Further studies have revealed 
that the presence of activating mutations in the EGFR kinase 
domain is strongly associated with the therapeutic efficacy of 
EGFR-TKIs.3,4
Randomized phase 3 trials have demonstrated that 
EGFR-TKIs significantly improve median progression-free 
survival (PFS) compared with platinum-doublet therapy in 
EGFR-mutated patients.5–8 However, not all mutations in the 
EGFR kinase domain are responsive to EGFR-TKI treatment. 
These phase 3 trials have shown that EGFR-TKIs are effective 
for patients with common EGFR mutations, such as an exon 
19 deletion or the L858R point mutation, which account for 
more than 90% of EGFR mutations. Retrospective studies and 
case reports suggest that some uncommon mutations are asso-
ciated with sensitivity to EGFR-TKIs.9–20 These mutations 
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include G719X in exon 18, which accounts for approximately 
3% of EGFR mutations, and L861Q in exon 21, which repre-
sents approximately 2% of EGFR mutations. However, these 
uncommon EGFR mutations have not been clearly shown to 
be predictive markers for the efficacy of EGFR-TKIs because 
of their low frequency.
To investigate the efficacy of gefitinib in patients with 
uncommon mutations, we conducted a post-hoc analysis of the 
NEJ002, which compared gefitinib and  carboplatin-paclitaxel 
as first-line therapies for advanced NSCLC with activating 
EGFR mutations.
PATIENTS AND METHODS
Patient Population
We retrospectively analyzed the data of 225 patients who 
received gefitinib treatment at any point in the NEJ002 study.6 
The eligibility criteria of the NEJ002 study included the pres-
ence of advanced NSCLC harboring an EGFR mutation (exon 
19 deletion or L858R, G719X, or L861Q point mutation) 
without the resistant EGFR mutation T790M (identified using 
the peptide nucleic acid–locked nucleic acid polymerase chain 
reaction clamp method), no history of chemotherapy, an age of 
75 years or younger, a performance status of 0 to 1, and appro-
priate organ function.21,22 Patients provided a written informed 
consent. The study was conducted in accordance with the 
Helsinki Declaration of the World Medical Association. The 
protocol was approved by the institutional review board of 
each participating institution.
Treatment
Eligible patients were randomly assigned to receive 
either gefitinib (250 mg/day) or paclitaxel (200 mg/m2)/car-
boplatin (area under the curve, 6.0) on day 1 every 3 weeks. 
Chemotherapy was continued for at least three cycles. 
Gefitinib was administered until the disease progressed, intol-
erable toxicities developed, or consent was withdrawn. The 
protocol recommended that the crossover regimen be used as 
a second-line treatment.
Clinical Assessments
The antitumor response to treatment was assessed 
using computed tomography every 2 months. Unidirectional 
measurements were adopted on the basis of the Response 
Evaluation Criteria in Solid Tumors (version 1.0).23 PFS was 
evaluated from the date of randomization to the date when 
disease progression was first observed or death occurred. The 
treatment response and PFS were determined by an external 
review of computed tomography scans by experts who were 
not aware of the treatment assignments. Overall survival (OS) 
was evaluated from the date of randomization to the date of 
death.
Statistical Analysis
To assess prognostic factors for OS, we used univariate 
and multivariate Cox proportional hazards models. Kaplan–
Meier survival curves were constructed for PFS and OS, and 
differences between groups were identified using the log-rank 
test. Differences in response rates were identified using 
Fisher’s exact test. Each analysis was two sided, with a 5% 
significance level and a 95% confidence interval. All analy-
ses were performed using SAS for Windows software (release 
9.1; SAS Institute, Cary, NC).
RESULTS
Patient Population
A total of 230 chemonaive patients were enrolled in 
the NEJ002 study: 115 patients were assigned to receive gefi-
tinib and 115 were assigned to receive  carboplatin-paclitaxel 
(Fig. 1). To evaluate the efficacy of gefitinib in NSCLC 
patients with uncommon EGFR mutations, we analyzed the 
data of 114 patients in the gefitinib group and 111 patients 
in the carboplatin-paclitaxel group. We identified five patients 
who had uncommon EGFR mutations in each group. Two 
patients, who had common mutations and were treated with 
first-line chemotherapy consisting of carboplatin-paclitaxel, 
were excluded from the PFS analysis in the NEJ002 study. 
However, both were treated with gefitinib and were included 
in this post-hoc analysis. The demographic and disease 
characteristics of the patients with uncommon EGFR muta-
tions were similar to those of patients with common EGFR 
mutations (Table 1). The characteristics of each patient with 
uncommon EGFR mutations are shown in supplementary 
Table S1 (Supplemental Digital Content 1, http://links.lww.
com/JTO/A494).
Survival Factors
In the univariate analysis of 225 patients who received 
gefitinib at any point, uncommon EGFR mutations had a sig-
nificant detrimental effect on survival (Table 2). We also iden-
tified performance statuses 1 and 2, distant metastasis, brain 
metastasis, stable disease, and progressive disease as signifi-
cant predictors of worse prognosis for standard chemotherapy 
and stable disease and progressive disease as significant pre-
dictors of worse prognosis for gefitinib. When these variables 
were included in the Cox proportional hazards model, we 
found that uncommon EGFR mutations, performance statuses 
1 and 2, stable disease and progressive disease for standard 
chemotherapy, and stable disease and progressive disease for 
gefitinib had significant hazard ratios (Table 2).
Uncommon EGFR Mutations and Survival
The Kaplan–Meier curve for OS for uncommon versus 
common EGFR mutations is shown in Figure 2A. The OS was 
significantly shorter among patients with uncommon EGFR 
mutations compared with OS of those with common EGFR 
mutations in the overall population (12 versus 28.4 months; 
p = 0.002). A significantly shorter survival time was observed 
in patients with uncommon EGFR mutations compared with 
survival time in those with common EGFR mutations in the 
gefitinib group (11.9 versus 29.3 months; p < 0.001) (Fig. 2B). 
However, a similar survival time was observed between the 
subgroups of uncommon and common EGFR mutations 
in the carboplatin-paclitaxel group (22.8 versus 28 months; 
p = 0.358) (Fig. 2C).
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To examine whether the sequence of platinum dou-
blet and gefitinib affected OS, we performed a further sub-
group analysis. The survival time tended to be shorter among 
patients receiving first-line gefitinib compared with the sur-
vival time among those receiving first-line carboplatin-pacli-
taxel in the uncommon EGFR mutation group (11.9 versus 
22.8 months; p = 0.102). Consistent with previous publica-
tions, a similar survival time was observed between patients 
receiving  first-line gefitinib and those receiving first-line 
 carboplatin-paclitaxel in the common EGFR mutation group 
(29.3 versus 28 months; p = 0.378).
Uncommon EGFR Mutations, PFS,  
and Response
In the gefitinib group, the median PFS was signifi-
cantly shorter for patients with uncommon EGFR mutations 
compared with median PFS of those with common EGFR 
mutations (2.2 versus 11.4 months; p < 0.001) (Fig. 3A). By 
contrast, the median PFS did not differ significantly between 
patients with uncommon EGFR mutations and those with 
common EGFR mutations in the carboplatin-paclitaxel group 
(5.9 versus 5.4 months; p = 0.847) (Fig. 3B). The objective 
response rate was significantly lower in patients with uncom-
mon EGFR mutations compared with the objective response 
rate in those with common EGFR mutations when treated 
with gefitinib (20% versus 76%; p = 0.017) (supplementary 
Table S2, Supplemental Digital Content 1, http://links.lww.
com/JTO/A494). By contrast, similar objective response 
rates were observed for patients with uncommon EGFR 
mutations and those with common EGFR mutations in the 
 carboplatin-paclitaxel group (20% versus 32%; p = 0.336) 
(supplementary Table S2, Supplemental Digital Content 1, 
http://links.lww.com/JTO/A494).
DISCUSSION
Recent studies suggest that NSCLC patients with uncom-
mon EGFR mutations are less responsive to EGFR-TKIs 
compared with patients with L858R and exon 19 deletions.9–20 
However, the efficacy of EGFR-TKIs in NSCLC patients with 
uncommon mutations has not been fully elucidated.
We conducted a post-hoc analysis of the NEJ002 study 
to evaluate the effectiveness of gefitinib against NSCLC with 
G719X or L861Q. The NEJ002 study, comparing gefitinib 
and standard carboplatin-paclitaxel chemotherapy as the 
first-line treatment for patients with EGFR mutations, dem-
onstrated no significant difference in OS between gefitinib 
and  carboplatin-paclitaxel.6 In contrast to other phase 3 trials 
investigating EGFR-TKIs for patients with common EGFR 
mutations of exon 19 deletion and L858R, the NEJ002 is 
the only study that included uncommon EGFR mutations of 
G719X and L861Q.
The current study clearly demonstrated that NSCLC 
patients with the uncommon EGFR mutations G719X and 
L861Q had shorter survival than the survival of those with 
an exon 19 deletion or L858R mutation (Fig. 2). Our results 
are consistent with other clinical studies on EGFR-TKIs in 
FIGURE 1.  Enrollment, randomization, and follow-up of the study patients.
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patients with uncommon EGFR mutations (supplementary 
Table S3, Supplemental Digital Content 1, http://links.lww.
com/JTO/A494). The overall response rate to EGFR-TKIs in 
patients with uncommon EGFR mutations was 41%, which is 
lower than the response rate to TKIs (62%–83%) of patients 
with common EGFR mutations.7,8,24 In the NEJ002 study, 
G719X included G719C and G719S. No patients harbored 
G719A. To investigate the effectiveness of gefitinib on each 
uncommon EGFR mutations, we evaluated the difference 
in OS between patients with uncommon EGFR mutations 
(G719C versus G719S and G719X versus L861Q). There was 
no significant difference between these subgroups (data not 
shown).
This study showed that the PFS and OS tended to be 
shorter among patients treated with first-line gefitinib com-
pared with PFS and OS among those treated with first-line 
carboplatin-paclitaxel in the uncommon EGFR mutation 
group (supplementary Table S2, Supplemental Digital Content 
1, http://links.lww.com/JTO/A494). We also found poor dis-
ease control rate with gefitinib in patients with uncommon 
mutations. Three of five patients with uncommon mutations 
in the gefitinib group had progressive disease. By contrast, no 
patients with uncommon mutations had progressive disease 
in the carboplatin-paclitaxel group. Although the number of 
patients with uncommon mutations in each treatment group 
was small, platinum-doublet therapy might be a better choice 
than gefitinib for first-line therapy in patients with uncom-
mon EGFR mutations. Because some of patients with uncom-
mon mutations showed good clinical response to gefitinib in 
this study and they seemed to be heterogeneous in terms of 
response to gefitinib, administration of gefitinib should be 
considered for patients with uncommon mutations when dis-
ease progression was observed after first-line chemotherapy.
In vitro studies have indicated that the affinity of gefi-
tinib for EGFR proteins with uncommon EGFR mutations 
is lower than the affinity of gefitinib for EGFR proteins with 
common EGFR mutations.25 A sixfold or 14-fold higher con-
centration of gefitinib was required to inhibit the growth of 
cells expressing G719X or L861Q, respectively, compared 
with cells expressing L858R.26 These results may explain 
the lack of response to gefitinib in patients with uncommon 
EGFR mutations. The authors also examined the sensitivity 
of G719X and L861Q mutations to erlotinib and irreversible 
TKIs.27 Cells expressing G719X were less resistant to erlo-
tinib than gefitinib in vitro; however, L861Q was resistant to 
both erlotinib and gefitinib. In contrast to erlotinib, irreversible 
TKIs inhibited the growth of cells with G719X or L861Q at a 
TABLE 1.  Patient Characteristics
Number of Patients
Uncommon Mutation
10
Common Mutation
215
Sex
  Female 4 139
  Male 6 76
Age (yr)
  Median 63 65
  Range 42–75 35–75
Smoking status
  Never smoked 5 134
  Smoker 5 81
Performance status
  0/1/2 5/5/0 105/107/3
Histology
  Adenocarcinoma 9 202
  Others 1 13
Clinical stage
  Stage IIIB 3 32
  Stage IV 6 165
  Postoperative 1 18
Type of EGFR mutation
  G719X 7
  L861Q 3
  Exon 19 deletion 115
  L858R 97
  19 deletion + L858R 3
EGFR, epidermal growth factor receptor.
TABLE 2.  Univariate and Multivariate Analysis by Cox Proportional Hazards Model
Univariate Multivariate
HR 95% CI p HR 95% CI p
Age (≥70/<70) 1.047 0.719–1.525 0.81
Sex (female/male) 0.73 0.51–1.045 0.86
Smoking status (+/−) 1.376 0.967–1.958 0.076
Performance status (1, 2/0) 1.792 1.263–2.541 0.001 1.85 1.297–2.639 0.001
Histology (nonadeno/adeno) 0.647 0.302–1.387 0.263
Types of EGFR-m (uncommon/common) 2.967 1.501–5.868 0.018 2.445 1.177–5.079 0.017
Distant metastasis (+/−) 4.914 1.113–5.741 0.027 2.849 1.241–6.54 0.135
Brain metastasis (+/−) 1.781 1.248–2.542 0.002 1.311 0.897–1.915 0.162
Response to Cb/TXL (SD, PD/CR, PR) 1.742 1.113–2.728 0.015 1.748 1.11–2.754 0.016
Response to G (SD, PD/CR, PR) 2.878 2.012–4.117 0.002 2.601 1.794–3.771 <0.001
HR, hazard ratio; CI, confidential interval; EGFR-m, epidermal growth factor receptor mutation; CR, complete response; PR, partial response; SD, stable disease; PD, progressive 
disease; Cb/TXL, carboplatin plus paclitaxel; G, gefitinib.
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lower concentration than those with wild-type EGFR. Indeed, 
Sequist et al.28 reported that the effectiveness of an irreversible 
pan-ErbB receptor TKI, neratinib, on NSCLC patients with 
G719X. Niratinib induced partial responses in three of four 
patients with G719X and the fourth had durable stable disease 
for 40 weeks. It may be beneficial to evaluate erlotinib as a 
treatment for NSCLCs with G719X and irreversible EGFR-
TKIs as treatments for NSCLCs with G719X and L861Q. 
Because previous phase 3 trials that investigated erlotinib or 
irreversible TKIs for NSCLC with EGFR mutations did not 
include uncommon EGFR mutations, further clinical studies 
may need to be performed.7,8,29
Another possible strategy for the treatment of uncom-
mon EGFR mutations is the combination of EGFR-TKIs and 
cytotoxic agents. Our group has undertaken a randomized 
phase 3 trial to compare gefitinib plus carboplatin plus peme-
trexed with gefitinib monotherapy for patients with NSCLC 
with an exon 19 deletion or an L858R, G719X, or L861Q 
EGFR mutation (NEJ009; University Hospital Medical 
Information Network Clinical Trials Registry [UMIN-CTR] 
number, UMIN000006340). The data from this study will 
advance the treatment of NSCLC with uncommon EGFR 
mutations.
In conclusion, our post-hoc analysis clearly demon-
strated shorter survival of TKI-treated patients with uncom-
mon EGFR mutations compared with survival of those with 
common EGFR mutations. Furthermore, the data suggest that 
the first-line chemotherapy may be relatively effective for 
NSCLC with uncommon EGFR mutations.
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FIGURE 2.  The overall survival curves of patients with 
common mutations and uncommon mutations in the 
entire population (A), the gefitinib group (B), and the 
 carboplatin-paclitaxel group (C).
FIGURE 3.  Progression-free survival curves in the gefitinib 
group (A) and the carboplatin-paclitaxel group (B) according 
to the type of epidermal growth factor receptor mutation.
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